| __timestamp | Madrigal Pharmaceuticals, Inc. | Viatris Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 15746000 | 1499100000 |
| Thursday, January 1, 2015 | 13392000 | 1923500000 |
| Friday, January 1, 2016 | 9290000 | 2351400000 |
| Sunday, January 1, 2017 | 7672000 | 2564000000 |
| Monday, January 1, 2018 | 15293000 | 2397300000 |
| Tuesday, January 1, 2019 | 22648000 | 2503400000 |
| Wednesday, January 1, 2020 | 21864000 | 3344600000 |
| Friday, January 1, 2021 | 37318000 | 4529200000 |
| Saturday, January 1, 2022 | 48130000 | 4179100000 |
| Sunday, January 1, 2023 | 108146000 | 4650100000 |
Data in motion
In the competitive landscape of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, Viatris Inc. and Madrigal Pharmaceuticals, Inc. have taken distinct paths in optimizing these costs.
From 2014 to 2023, Viatris Inc. consistently reported higher SG&A expenses, peaking at approximately $4.65 billion in 2023. This represents a steady increase of over 200% from their 2014 figures. In contrast, Madrigal Pharmaceuticals, Inc. maintained a more conservative approach, with their SG&A expenses growing from around $15 million in 2014 to $108 million in 2023, marking a significant increase of over 600%.
While Viatris's larger scale justifies its higher expenses, Madrigal's rapid growth in SG&A costs suggests aggressive expansion strategies. Understanding these trends offers valuable insights into each company's operational priorities and market strategies.
Breaking Down SG&A Expenses: Zoetis Inc. vs Viatris Inc.
Alnylam Pharmaceuticals, Inc. and Viatris Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Viatris Inc. and Ascendis Pharma A/S
SG&A Efficiency Analysis: Comparing Viatris Inc. and BioMarin Pharmaceutical Inc.
Selling, General, and Administrative Costs: Viatris Inc. vs Ultragenyx Pharmaceutical Inc.
Operational Costs Compared: SG&A Analysis of Viatris Inc. and Corcept Therapeutics Incorporated
Who Optimizes SG&A Costs Better? Viatris Inc. or CRISPR Therapeutics AG
Cost Management Insights: SG&A Expenses for Viatris Inc. and BioCryst Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. vs Bausch Health Companies Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Madrigal Pharmaceuticals, Inc. and ImmunityBio, Inc.
Who Optimizes SG&A Costs Better? Madrigal Pharmaceuticals, Inc. or MannKind Corporation
Operational Costs Compared: SG&A Analysis of Madrigal Pharmaceuticals, Inc. and Xencor, Inc.